Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

Registos relacionados

• Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
  Por: Jassem, Jacek
  Publicado em: (2019)
• Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress
  Por: Pennell, Nathan A.
  Publicado em: (2012)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  Por: Oxnard, Geoffrey R., et al.
  Publicado em: (2011)
• Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?
  Por: Liang, Wenhua, et al.
  Publicado em: (2015)
• <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
  Por: Xavier Cansouline, et al.
  Publicado em: (2022-04-01)